The French drug giant Sanofi-Aventis is giving Cambridge, MA-based Genzyme’s (NASDAQ:[[ticker:GENZ]]) stockholders until January 21, or six more weeks, to accept its buyout offer of $69 per share, Reuters and other news outlets reported this morning. Sanofi’s previous deadline for its offer to acquire shares of Genzyme, the largest biotech company in Massachusetts, was last Friday. Genzyme has said Sanofi’s unsolicited $18.5 billion buyout offer undervalues the company and its pipeline of drugs.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
